28/10/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with masitinib Download PDF Post navigationPreviousPrevious post:AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSNextNext post:Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CETRelated PostsSummary of the webcast held on January 28, 202529 January 2025Summary of the webcast held on December 16, 202417 December 2024AB Science webcast of December 16, 202416 December 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET11 December 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024Revenues for the first half of 2024 and update on AB Science’s activities10 October 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS17 October 2024
